Ï Ä.Ì. åîïìïëïãåßôáé...

Boy Ç éóôïñßá ìïõ åßíáé ëßãï-ðïëý ßäéá ìå áñêåôþí üóùí Ý÷ïõí ãñÜøåé åäþ.

¸÷ïõìå ðïëëÜ êïéíÜ. Êé åãþ êÜðùò Ýôóé óêÝöôçêá íá ãñÜøù ôç äéêÞ ìïõ éóôïñßá.

Åßìáé 26 ÷ñïíþí êáé Ýìáèá ðùò åßìáé ïñïèåôéêüò ìüëéò ðñéí áðü ìéá åâäïìÜäá.

Ìéá öïñÜ áðåñéóêåøßáò Þôáí áñêåôÞ ãéá íá ôçí ðáôÞóù êáé ãéá üóïõò ðéóôåýïõí üôé åäþ óôçí ÅëëÜäá äåí êéíäõíåýåéò ðïëý, Ý÷ù íá ðù ðùò åãþ ôï Ýðáèá öõóéêÜ åäþ. ÐïõèåíÜ áëëïý.

Ôçí ðÜôçóá ìå ìüíï ìéá öïñÜ ÷ùñßò ðñïöõëáêôéêü, ìå Ýíáí ðïëý ìéêñüôåñü ìïõ óôçí çëßêéá. ÊÜðïéïé ößëïé ìïõ åß÷áí ðåé ôüôå üôáí ôïõò åéðá ðùò Ýêáíá ìáëáêéá êáé ôïí Üöçóá íá êÜíïõìå óåî ÷ùñßò ðñïöõëáêôéêü: «¢íôå ñå, ìçí áíçóõ÷åßò. Áõôü åßíáé ó÷åäüí ìùñü áêüìá...».
Ðïëëïß èåùñïýí ðùò åßíáé èÝìá çëéêéáò êáé üôé áí ðáò ìå êÜðïéïí ìéêñüôåñï, äåí Ý÷åéò öüâï.

¸êáíá ôñßá åðáíáëçðôéêÜ ôåóô ìÝ÷ñé ôåëéêÜ íá äéáðéóôþóù üôé Ý÷ù ìïëõíèåß ìå ôïí HIV.
Óôï éäéùôéêü åñãáóôÞñéï üðïõ Ýêáíá ôçí ðñþôç åîÝôáóç ãéá HIV Þôáí ðïëý äéáêñéôéêïß. Ìïõ åßðáí üôé ôï áðïôÝëåóìá Þôáí ïñéáêÜ èåôéêü êáé üôé ÷ñåéáæüôáí áðáñáßôçôá åðéâåâáßùóç.
Ôþñá ðüóï ïñéáêü Þ îåêÜèáñï Þôáí, Ýíáò Èåüò ôï îÝñåé.

Óôï äçìüóéï íïóïêïìåßï üðïõ ìå Ýóôåéëáí ãéá ðåñáéôÝñù åîåôÜóåéò, ïé íïóïêüìåò êÜèå öïñÜ ðïõ ìå êïßôáãáí Þôáí óáí íá ìïõ ôï óéãïõñåýïõí.

¸êáíáí íåýìáôá ðïõ êáé êáëÜ íüìéæáí üôé äåí Ýâëåðá.
ØéèõñéóôÝò óõíïìéëßåò ôçí þñá ðïõ ðåñéìåíá. ÊÜðïéïé óõíáäåëöïß ôïõò ðïõ Ýâãáéíáí íá äïõí êáé êáëÜ áí êïõíéïýíôáé ïé âÜñêåò.
Äåí Þîåñá åáí Ýðñåðå íá êëÜøù Þ íá ãåëÜóù ìå áõôÞ ôçí êáôÜóôáóç.
Áðü ôçí Üëëç âÝâáéá ìðïñåß üðïéïò Ý÷åé ôç ìýãá íá ìõãéÜæåôáé, üðùò ëÝíå...

Ìüëéò Ýêáíá ôï äåýôåñï ôåóô ãéá HIV, Üñ÷éóá íá øÜ÷íù óôï ßíôåñíåô ðëçñïöïñßåò ãéá ôï AIDS áëëÜ äõóôõ÷þò äåí âñÞêá ðïëëÝò ó÷åôéêÝò éóôïóåëßäåò áðü ÅëëÜäá, ïðüôå Ýöôáóá ãñÞãïñá óå áõôÞí åäþ.

Eßìáé áñêåôÜ áéóéüäïîïò êáé åëðßæù ïôé áõôÜ ðïõ èÝëù íá êÜíù óôï ìÝëëïí, èá êáôáöÝñù ôåëéêÜ íá ôá êÜíù. ¸óôù êáé áí ðáñïõóéáóôïýí êÜðïéåò äõóêïëßåò óôï ìÝëëïí ëüãù ôçò áóèÝíåéÜò ìïõ.

¹èåëá íá ðù ðùò ôï íá åßìáé óå ìéá ó÷åôéêÜ Þñåìç øõ÷ïëïãéêÞ êáôÜóôáóç - ïýôå ðïëý êáëÜ, áëëÜ ïýôå êáé ðïëý óôåíá÷ùñçìÝíïò ìå êëÜììáôá êáé ôÝôïéá (åêôüò ôçò ðñþôçò ìÝñáò ðïõ ôï Ýìáèá) - âïÞèçóáí ïé éóôïñßåò ðïõ äéÜâáóá åäþ.

Íéþèù üôé åßìáé äõíáôüò ãéá íá ôï áíôéìåôùðßóù êáé åëðßæù ðùò ìå ôçí âïÞèåéá ôùí ãéáôñþí, üëá èá ðÜíå êáëÜ.

Ç æùç óõíå÷ßæåôáé... óôï ìÜîéìïõì!




... 'Aëëåò éóôïñßåò ...



Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Optimised second-line regimens in the public health approach

Globally, most people receive antiretroviral therapy (ART) in programmes that follow the WHO-recommended public health approach, using a small number of standard regimens and simplified monitoring.1 A single standard regimen—dolutegravir (an integrase strand transfer inhibitor [INSTI]) with tenofovir disoproxil fumarate and lamivudine (both nucleoside reverse transcriptase inhibitors, [NRTIs])—is currently taken by the large majority of people on ART in these programmes, including those on second-line therapy (following previous failure of a non-NRTI regimen).

Prioritising HIV drug resistance testing according to risk

Tenofovir–lamivudine–dolutegravir (TLD) is recommended as an initial treatment regimen and a preferred optimised regimen for people living with HIV without a history of previous viral non-suppression, referred to as TLD in first-line therapy (TLD-1). For people living with HIV with persistent viral non-suppression, TLD largely replaced protease inhibitor-based regimens following efavirenz-based initial regimens, referred to as TLD in second-line therapy (TLD-2), as it is at least as effective, better tolerated, and more affordable.

Ending paediatric AIDS: time to close implementation gaps

WHO's global health sector strategies on HIV, conceived to guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS by 2030, target a reduction in the number of children aged 0–14 years newly infected with HIV from 150 000 in 2022 to 20 000 in 2025 and 15 000 in 2030.1 To track progress toward these targets, accurate estimations of the number of annual infections in children in each country is crucial. However, in many low-income and middle-income countries, where the burden of paediatric HIV is the highest, children are not systematically tested for HIV in programmes for the prevention of vertical transmission (PVT).

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò